Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by GunnerGon Jun 20, 2021 9:18pm
73 Views
Post# 33418600

RE:USD$5 million is just initial payment in the contract.

RE:USD$5 million is just initial payment in the contract.GoldenJJ, it says ;

"(b) In the event the BLA and/or the PRV is issued [***], subsequent to Kedrion exercising its Call Option, the amount of the Milestone Payment shall be increased to an amount equal to [***]."

BLA and PRV were issued prior to Kedrion exercising, not subsequent.


GoldenJJ wrote: It says the milestone payment will be increased if ryplazim is approved by FDA https://app.quotemedia.com/data/downloadFiling?webmasterId=101442&ref=115890350&type=HTML&symbol=LMNL&companyName=Liminal+BioSciences+Inc.&formType=6-K&formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&dateFiled=2021-05-21&CK=1351172


<< Previous
Bullboard Posts
Next >>